Novo Nordisk Discloses Insider Share Transactions
Ticker: NONOF · Form: 6-K · Filed: Aug 30, 2024 · CIK: 353278
Sentiment: neutral
Topics: insider-trading, disclosure, regulation
TL;DR
Novo Nordisk just dropped insider trading data - check it out!
AI Summary
Novo Nordisk A/S announced on August 30, 2024, that it is disclosing transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Why It Matters
This filing provides transparency into the trading activities of company insiders, which can offer insights into their confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of insider trading activity and does not contain new financial information or strategic changes.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant
- Regulation No. 596/2014 (regulation) — Governing market abuse disclosures
- August 30, 2024 (date) — Date of announcement
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to disclose transactions in Novo Nordisk shares made by the company's board members, executives, and their associated persons, in accordance with market abuse regulations.
When was this company announcement made?
The company announcement was made on August 30, 2024.
Which regulation governs these disclosures?
These disclosures are made in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
What type of transactions are being disclosed?
The filing discloses transactions in Novo Nordisk shares by board members, executives, and their associated persons.
Is Novo Nordisk filing a Form 20-F or 40-F annually?
Novo Nordisk indicates it files annual reports under cover of Form 20-F.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-08-30 10:14:26
Filing Documents
- f6k_083024.htm (6-K) — 26KB
- ca.jpg (GRAPHIC) — 11KB
- logo.jpg (GRAPHIC) — 76KB
- 0001171843-24-004992.txt ( ) — 148KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: August 30, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer